Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022 is a dataset published in Arthritis & Rheumatology (2024). On theSindex it has a DataRank of 0.497, placing it in the top 38.5% of the data-sharing corpus. It has been cited 7 times, with 5 citing works in its 1-hop citation network.
Ranks in the top 39% for downstream scientific impact
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.312
From this paper's citation signal
Citation Network Contribution
0.185
From 3 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 5 citers.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
Grant: K24 AR074534
Agency for Healthcare Research and Quality
Grant: R01 HS028024
NIAMS NIH HHS
Grant: P30 AR075055
American College of Rheumatology's Rheumatology Informatics System for Effectiveness registry
FWCI
1.35
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords